Patent US4269848A successfully refreshed from Google Patents.
US4269848A
Expired / Lapsed
US
⏱️ 0.0 years remaining
5-Substituted indan-2-carboxylic acid and functional derivatives
Assignee: Merck Sante SAS
•
Filing: 1978-01-27
•
Granted: 1981-05-26
•
Expires: 1998-01-27
Abstract
Abstract 5-Substituted indan-2-carboxylic acids and functional derivatives thereof having inflammation-reducing properties have the general formula ##STR1## in which R is a phenyl, phenyl-lower alkenyl, phenyl-lower alkyl, phenyl substituted by at least one of the halogens, lower alkyl, lower alkoxy, acetamido, amino, lower dialkylamino, nitro, phenyl, lower alkylsulfonyl, lower dialkylaminosulfonyl and sulfamido, cyclohexyl, furyl, lower alkylfuryl, thienyl, halothienyl, lower alkylthienyl, or pyridyl group and R' is a hydroxyl, lower alkoxy, lower dialkylaminoalkoxy, cinnamoylamido lower alkoxy, 2-hydroxyethylamino, amino or lower dialkylaminoalkyl amino group. Besides the esters and amides, the functional derivatives of the acids include the pharmacologically acceptable salts of the above compounds. The compounds are also of low toxicity, have analgesic activity and exert an antipyretic effect.
Inventors
- 👤 Michel Bayssat
- 👤 Francis Sautel
- 👤 Jean-Claude Depin
- 👤 Annie B. Matibet
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-01 18:41
CPC Classifications
C; C07; C07D; C07D213/00; C07D213/02; C07D213/04; C07D213/60; C07D213/78; C07D213/79; C07D213/80; A; A61; A61P; A61P25/00; A61P25/04; A61P29/00; C07C; C07C45/00; C07C45/004; C07C45/45; C07C45/46; C07C45/61; C07C45/63; C07C49/00; C07C49/76; C07C49/782; C07C49/784; C07C49/84; C07D213/24; C07D213/44; C07D213/46; C07D213/50; C07D307/00; C07D307/02; C07D307/34; C07D307/38; C07D307/40; C07D307/46; C07D333/00; C07D333/02; C07D333/04; C07D333/06; C07D333/22; C07D333/26; C07D333/28
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
60 words
A 5-substituted indan-2-carboxylic acid, or functional derivative thereof, having the formula: ##STR32## in which R is selected from the group consisting of furyl, alkylfurl, pyridyl, theinyl, and thienyl substituted by at least one of the substituents selected from the group consisting of halogen atoms and alkyl groups, in the free form or a therapeutically acceptable salt, ester or amide thereof.
Claim 2
Dependent Claim
60 words
A 5-substituted indan-2-carboxylic acid, or functional derivative thereof, having the formula: ##STR32## in which R is selected from the group consisting of furyl, alkylfurl, pyridyl, theinyl, and thienyl substituted by at least one of the substituents selected from the group consisting of halogen atoms and alkyl groups, in the free form or a therapeutically acceptable salt, ester or amide thereof.
Claim 3
Dependent Claim
34 words
The compound of claim 1 wherein said therapeutically acceptable ester or amide is selected from the group consisting of the alkyl, dialkylaminoalkyl and cinnamoylamidoalkyl carboxylic acid esters and the dihydro, 2-hydroxyethyl and dialkylaminoalkyl carboxamides.
Claim 4
Dependent Claim
32 words
The compound of claim 1 wherein R is furyl, alkylfuryl, thienyl or thienyl substituted by at least one of the substituents selected from the group consisting of halogen atoms and alkyl groups.
Claim 5
Dependent Claim
33 words
The compound of claim 1 wherein R is furyl, furyl substituted by a methyl radical, thienyl or thienyl substituted by at least one substituent selected from the group consisting of chlorine and methyl.
Claim 6
Dependent Claim
20 words
The compound of claim 1 in the form of a therapeutically acceptable ester wherein said ester comprises the dialkylaminoalkyl ester.
Claim 7
Dependent Claim
29 words
The compound of claim 1 wherein R is a thienyl or substituted thienyl radical, in the form of a therapeutically acceptable amide, wherein sad amide comprises the dialkylaminoalkyl carboxamide.
Claim 8
Dependent Claim
28 words
A therapeutic composition for combatting inflammation and pain comprising an anti-inflammatory or analgesic amount of a compound in accordance with claim 1 and a pharmaceutically acceptable excipient therefor.
Claim 9
Dependent Claim
23 words
The composition in accordance with claim 7 in unit dosage form, each unit dose comprising from 50 to 500 mg of said compound.
References Cited (Backward Citations)
US3953500A
Cited
US4057573A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1984-05-25 | 1984-11-24 | 1985-05-26 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1988-05-25 | 1988-11-24 | 1989-05-26 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1992-05-25 | 1992-11-24 | 1993-05-26 | $7700.00 | Window Closed / Lapsed |